Study of an oral medication for moderate to severe plaque psoriasis
Part of Skin clinical trials.
This study tests an experimental oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing psoriasis symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You weigh more than 88 pounds (40 kg) and have a body mass index (BMI) between 18 and 40.
- You have had plaque psoriasis (raised, red, scaly patches) for at least 6 months.
- If you could become pregnant or could get someone pregnant, you must agree to use effective birth control during the study.
- You have not taken a TYK2 inhibitor before, and you have not used certain other psoriasis treatments recently (like biologics or strong immune-suppressing drugs).
- You do not have a serious infection like untreated tuberculosis, or a history of certain autoimmune diseases other than psoriasis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests an experimental oral tablet (UA026) in people with moderate to severe plaque psoriasis. The purpose is to see how safe and effective the drug is, and how it works in the body.
This study tests an oral medication (HSK47388) as a treatment for moderate-to-severe plaque psoriasis, the most common type. It may help reduce symptoms like red, scaly patches and improve quality of life.
This trial tests an investigational drug called ORKA-002 for people with moderate-to-severe plaque psoriasis. It aims to see how well different doses work and if they are safe. You may qualify if your psoriasis covers at least 10% of your body or if it has not responded well enough to other treatments.
This study tests an investigational medicine (HS-20118) for people with moderate-to-severe plaque psoriasis. The goal is to see if the drug can safely and effectively reduce psoriasis symptoms and improve quality of life.
This study tests a new medicine (HS-20137) for moderate-to-severe plaque psoriasis, a condition causing thick, scaly patches on the skin. It aims to see if this medicine can safely reduce the severity of psoriasis and improve quality of life.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.